Clinical Importance of Anti-Human Leukocyte Antigen-Specific Antibody Concentration in Performing Calculated Panel Reactive Antibody and Virtual Crossmatches
Author:
- 15 April 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 85 (7) , 1046-1050
Abstract
Background. Highly sensitized patients develop multi-human leukocyte antigen (HLA) specific antibodies. This study measures concentrations of anti-HLA antibodies in multispecific sera by converting fluorescence intensity into molecules of equivalent soluble fluorochrome (MESF) units. This was used to determine MESF units required for a positive T and B flow crossmatches (FLXM). Methods. MESF values of negative controls and sera from patients devoid of HLA antibodies were measured by FLXM and flow panel reactive antibody (PRA) screening beads. Fluorescence intensity values of anti-HLA specific antibodies determined by FlowPRA single antigen beads of highly sensitized patients were converted into MESF units. In addition, endpoint titers, MESF units, and % PRA of 26 sera were established. Results. MESF analysis accurately predicted the outcomes of 100% of T and B FLXM of sera with strong (MESF units>18,000) donor-specific antibody (DSA). The predictive values of T and B FLXM declined to 95% and 88% with weak DSA (6,000 MESF2,000). The graft survival at 1 year was 100% and there was no evidence of DSA posttransplant. Conclusion. MESF analysis is both a time and cost efficient way of measuring antibody strength. The strength of the antibody present in the sera of transplant candidates is critical for crossmatch prediction.Keywords
This publication has 11 references indexed in Scilit:
- The Importance of Anti-HLA-Specific Antibody Strength in Monitoring Kidney Transplant PatientsAmerican Journal of Transplantation, 2007
- Prediction of Crossmatch Outcome of Highly Sensitized Patients by Single and/or Multiple Antigen Bead Luminex AssayTransplantation, 2006
- A Comparison of Plasmapheresis Versus High-Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific AlloantibodyAmerican Journal of Transplantation, 2006
- Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1Transplantation, 2004
- Formalization of the MESF unit of fluorescence intensityCytometry Part B: Clinical Cytometry, 2003
- Pre-Transplant Assessment of Donor-Reactive, HLA-Specific Antibodies in Renal Transplantation: Contraindication vs. RiskAmerican Journal of Transplantation, 2003
- Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patientsTransplantation, 2003
- IMPROVED FLOW CYTOMETRIC DETECTION OF HLA ALLOANTIBODIES USING PRONASETransplantation, 2001
- Fluorescence Intensity Calibration for Immunophenotyping by Flow CytometryMethods, 2000
- Flow cytometric quantitation of immunofluorescence intensity: Problems and perspectivesCytometry, 1998